Socio-demographic Profile and Economic Burden of Treatment of Transfusion Dependent Thalassemia

Original Article

Abstract

Objective

To compile the socio-demographic profile and estimate the economic burden of transfusion dependent thalassemia.

Methods

This cross-sectional descriptive study was conducted at a tertiary care hospital in north India. Transfusion dependent thalassemia patients on regular blood transfusion for at least a year were selected. Thalassemia diagnosis was based on HPLC and/or mutation analysis results. Clinical and laboratory parameters were collected from electronic health records. Information regarding socio-economic profile and costs incurred, including indirect costs were collected by interviewing patients’ guardians. The data was analyzed as a whole cohort and also in subgroups based on age.

Results

The data of 261 patients with a median age of 127 mo was collected. The median age at diagnosis was 9.8 mo. The total treatment expenses of a patient per year ranged from US$ 629 (INR 41,514) to US$ 2300 (INR 151,800), in the different age groups, at an average of US$ 1135 (INR 74,948). More than half (53%) of this was spent on medications. On an average, 38.8% of the family income was spent on the treatment of a thalassemia patient annually. Only 19 of 262 cases had an average pre-BT Hb ≥ 9 g/dl and serum ferritin ≤1500 ng/dl.

Conclusions

The treatment for transfusion dependent thalassemia is costly and mostly borne by the families in India. This study provides a realistic magnitude of this burden and will be useful in planning a thalassemia management program at the state or national level.

Keywords

Thalassemia Economic burden Demographic study 

Notes

Acknowledgements

The authors thank Mr. Avinash Pandey and Ms. Neera for their assistance in data collection.

Contributions

AM collected the data, drafted the manuscript; SRP conceptualized the study, edited the manuscript and will act as guarantor for this paper.

Compliance with Ethical Standards

Conflict of Interest

None.

Source of Funding

None.

Supplementary material

12098_2017_2478_MOESM1_ESM.docx (18 kb)
ESM 1(DOCX 17 kb)

References

  1. 1.
    Birth defects in south-East Asia: a public health challenge Situation Analysis. WHO. 2013. p. 38-41. http://www.searo.who.int/entity/child_adolescent/documents/sea_cah_13/en/.
  2. 2.
    Verma IC, Saxena R, Kohli S. Past, present & future scenario of thalassemic care & control in India. Indian J Med Res. 2011;134:507–21.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Mohanty D, Colah RB, Gorakshakar AC, et al. Prevalence of b-thalassemia and other haemoglobinopathies in six cities in India: a multicenter study. J Community Genet. 2013;4:33–42.CrossRefPubMedGoogle Scholar
  4. 4.
    Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008;86:480–7.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Weatherall DJ. Keynote address: the challenge of thalassemia for the developing countries. Ann N Y Acad Sci. 2005;1054:11–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Weatherall DJ. The challenge of haemoglobinopathies in resource-poor countries. Br J Haematol. 2011;154:736–44.CrossRefPubMedGoogle Scholar
  7. 7.
    Sangani B, Sukumaran PK, Mahadik C, et al. Thalassaemia in Bombay: the role of medical genetics in developing countries. Bull World Health Organ. 1990;68:75–81.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Trehan A, Sharma N, Das R, Bansal D, Marwaha RK. Clinico-investigational and demographic profile of children with thalassemia major. Indian J Hematol Blood Transfus. 2015;31:121–6.Google Scholar
  9. 9.
    Ware HM, Kwiatkowski JL. Evaluation and treatment of transfusional iron overload in children. Pediatr Clin N Am. 2013;60:1393–406.CrossRefGoogle Scholar
  10. 10.
    Riewpaiboon A, Nuchprayoon I, Torcharus K, Indaratna K, Thavorncharoensap M, Ubol BO. Economic burden of beta-thalassemia/Hb E and beta-thalassemia major in Thai children. BMC Res Notes. 2010;3:29.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Ginsberg G, Tulchinsky T, Filon D, Goldfarb A, Abramov L, Rachmilevitz EA. Cost-benefit analysis of a national thalassaemia prevention programme in Israel. J Med Screen. 1998;5:120–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Scalone L, Mantovani LG, Krol M, et al. Costs, quality of life, treatment satisfaction and compliance in patients with beta-thalassemia major undergoing iron chelation therapy: the ITHACA study. Curr Med Res Opin. 2008;24:1905–17.CrossRefPubMedGoogle Scholar
  13. 13.
    Mallik S, Chatterjee C, Mandal PK, Sardar JC, Ghosh P, Manna N. Expenditure to treat thalassaemia: an experience at a tertiary care hospital in India. Iran J Publ Health. 2010;39:78–84.Google Scholar
  14. 14.
    Tamhankar PM, Agarwal S, Arya V, Kumar R, Gupta UR, Agarwal SS. Prevention of homozygous beta thalassemia by premarital screening and prenatal diagnosis in India. Prenat Diagn. 2009;29:83–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Amid A, Saliba AN, Taher AT, Klaassen RJ. Thalassaemia in children: from quality of care to quality of life. Arch Dis Child. 2015;100:1051–7.CrossRefPubMedGoogle Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2017

Authors and Affiliations

  1. 1.Department of Medical GeneticsSanjay Gandhi Postgraduate Institute of Medical SciencesLucknowIndia

Personalised recommendations